BridgeBio Pharma Shares Plunge 8.94% as $620M Trading Volume Surges 126.94% to Top 500-Stock Volume Rankings Despite $110M Revenue Growth and 3,751 Prescriptions for Attruby

BridgeBio Pharma (BBIO) closed 8.94% lower on August 6, with a trading volume of $620 million, up 126.94% from the prior day. The decline followed mixed reactions to its Q2 2025 earnings, which showed $110.6 million in revenue driven by $71.5 million in U.S. Attruby net product sales. Despite robust revenue growth, the company reported a net loss of $183.8 million, widening from $75.5 million in the same period last year.

The earnings highlighted Attruby’s commercial progress, with 3,751 unique patient prescriptions as of August 1, 2025. Clinical data reinforced its efficacy, including a 59% relative risk reduction in time to adverse events for variant ATTR-CM patients and a 31.6% mortality reduction linked to early TTR stabilization. Pipeline updates included topline results expected in late 2025 for BBP-418 (LGMD2I/R9) and encaleret (ADH1), with infigratinib for achondroplasia advancing toward a 2026 Phase 3 readout. The company ended the quarter with $756.9 million in cash, supporting ongoing trials and commercial efforts.

Analysts noted challenges, including rising operating expenses and competitive pressures in the ATTR-CM market. Despite these, Attruby’s rapid adoption and clinical differentiation were seen as catalysts for long-term growth. The stock’s post-earnings rebound—3.71% in a single session—reflected investor confidence in its pipeline and cash position, though volatility remains a key risk.

The strategy of purchasing the top 500 stocks by daily trading volume and holding for one day delivered a 166.71% return from 2022 to the present, outperforming the benchmark return of 29.18% by 137.53%. This underscores the role of liquidity concentration in short-term stock performance, particularly in volatile markets.